Skip to main content
SRZN
NASDAQ Life Sciences

Major Investor Group, Including Director, Boosts Stake in Surrozen with $6M in Recent Stock Purchases

Analyse IA par Wiseek
Sentiment info
Positif
Importance info
9
Prix
$20.25
Cap. de marche
$171.386M
Plus bas 52 sem.
$5.9
Plus haut 52 sem.
$24.94
Market data snapshot near publication time

summarizeResume

The Column Group, a significant institutional investor in Surrozen, Inc., along with its managing partners including board member Tim Kutzkey, has substantially increased its beneficial ownership through a series of stock purchases totaling approximately $6.0 million. These purchases, made between November 2025 and January 2026, represent a significant vote of confidence from a key long-term investor and director, indicating a strong belief in the company's future prospects. The aggregated purchases amount to approximately 3.5% of the company's current market capitalization, signaling a material increase in their commitment.


check_boxEvenements cles

  • Significant Insider Buying

    The Column Group, a major institutional investor, reported approximately $6.0 million in stock purchases between November 2025 and January 2026.

  • Increased Beneficial Ownership

    The purchases, made by affiliated funds, represent a substantial increase in their stake, now totaling 35.1% of the company's common stock for individuals Tim Kutzkey (a director) and Peter Svennilson.

  • Director Confidence

    Tim Kutzkey, a member of Surrozen's board of directors, is part of the reporting group, signaling strong insider confidence.

  • Material Investment

    The aggregated purchases amount to approximately 3.5% of Surrozen's market capitalization, indicating a material commitment from a key investor.


auto_awesomeAnalyse

The Column Group, a significant institutional investor in Surrozen, Inc., along with its managing partners including board member Tim Kutzkey, has substantially increased its beneficial ownership through a series of stock purchases totaling approximately $6.0 million. These purchases, made between November 2025 and January 2026, represent a significant vote of confidence from a key long-term investor and director, indicating a strong belief in the company's future prospects. The aggregated purchases amount to approximately 3.5% of the company's current market capitalization, signaling a material increase in their commitment.

Au moment de ce dépôt, SRZN s'échangeait à 20,25 $ sur NASDAQ dans le secteur Life Sciences, pour une capitalisation boursière d'environ 171,4 M $. La fourchette de cours sur 52 semaines allait de 5,90 $ à 24,94 $. Ce dépôt a été évalué avec un sentiment de marché positif et un score d'importance de 9 sur 10.

descriptionVoir le depot SEC principal

show_chartGraphique des prix

Partager cet article

Copied!

feed SRZN - Dernieres analyses

SRZN
Mar 30, 2026, 6:21 PM EDT
Filing Type: 424B5
Importance Score:
7
SRZN
Mar 25, 2026, 8:02 PM EDT
Filing Type: 4
Importance Score:
8
SRZN
Mar 23, 2026, 5:26 PM EDT
Filing Type: S-3
Importance Score:
9
SRZN
Mar 23, 2026, 4:30 PM EDT
Filing Type: 10-K
Importance Score:
9
SRZN
Mar 23, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
8
SRZN
Mar 23, 2026, 4:05 PM EDT
Source: Reuters
Importance Score:
8
SRZN
Mar 16, 2026, 7:05 PM EDT
Filing Type: 4
Importance Score:
7
SRZN
Jan 22, 2026, 6:55 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
SRZN
Jan 20, 2026, 7:35 PM EST
Filing Type: 4
Importance Score:
7
SRZN
Jan 08, 2026, 5:19 PM EST
Filing Type: 4
Importance Score:
7